WITHDRAWN—a resource for withdrawn and discontinued drugs
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Post-marketing drug withdrawals can be associated with various events, ranging from safety issues such as reported deaths or severe side-effects, to a multitude of non-safety problems including lack of efficacy, manufacturing, regulatory or business issues. During the last century, the majority of drugs voluntarily withdrawn from the market or prohibited by regulatory agencies was reported to be related to adverse drug reactions. Understanding the underlying mechanisms of toxicity is of utmost importance for current and future drug discovery. Here, we present WITHDRAWN, a resource for withdrawn and discontinued drugs publicly accessible at http://cheminfo.charite.de/withdrawn. Today, the database comprises 578 withdrawn or discontinued drugs, their structures, important physico-chemical properties, protein targets and relevant signaling pathways. A special focus of the database lies on the drugs withdrawn due to adverse reactions and toxic effects. For approximately one half of the drugs in the database, safety issues were identified as the main reason for withdrawal. Withdrawal reasons were extracted from the literature and manually classified into toxicity types representing adverse effects on different organs. A special feature of the database is the presence of multiple search options which will allow systematic analyses of withdrawn drugs and their mechanisms of toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common toxicity types associated with drug withdrawals in the United States and Europe are hepatic (21%), cardiovascular (16%), hematological (11%), neurological (9%), and carcinogenicity (8%) (Figure 2) (20).”
From Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2
Adzhubei, I., Jordan, D. M., & Sunyaev, S. R. (2013) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0720s76 · Cited by 3,705 · cited 1×
“Furthermore, the information on biological pathways and SNPs, including amino acid changes, peptide positions, MAFs, PolyPhen scores (37) and links to dbSNP, were added in the detailed record of a target.”
BackgroundData, information, knowledge and principle: back to metabolism in KEGG
Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1076 · Cited by 3,092
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
An Algorithm for Subgraph Isomorphism
Ullmann, J. R. (1976) · Journal of the ACM · doi:10.1145/321921.321925 · Cited by 2,277
The ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492
UniProt Knowledgebase: a hub of integrated protein data
Magrane, M., & Consortium, U. (2011) · Database · doi:10.1093/database/bar009 · Cited by 1,463
Cunningham, F., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1010 · Cited by 1,115
Timing of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“including myocardial infarctions and stroke (40).”
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
The ConsensusPathDB interaction database: 2013 update
Kamburov, A., Stelzl, U., Lehrach, H., & Herwig, R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1055 · Cited by 807
The BioMart community portal: an innovative alternative to large, centralized data repositories
Smedley, D., Haider, S., Durinck, S., Pandini, L., Provero, P., Allen, J., Arnaiz, O., Awedh, M. H., Baldock, R., Barbiera, G., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv350 · Cited by 755 · cited 1×
“To extract the SNP information from dbSNP for the human protein targets within our database, the BioMart R package (32) was used.”
MethodProTox: a web server for the in silico prediction of rodent oral toxicity
Drwal, M. N., Banerjee, P., Dunkel, M., Wettig, M. R., & Preissner, R. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku401 · Cited by 738
Self-citationPhase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697
Wang, Y., Xiao, J., Suzek, T. O., Zhang, J., Wang, J., Zhou, Z., Han, L., Karapetyan, K., Dracheva, S., Shoemaker, B. A., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1132 · Cited by 659
dbSNP: a database of single nucleotide polymorphisms
Smigielski, E. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.352 · Cited by 621
The RCSB Protein Data Bank: views of structural biology for basic and applied research and education
Rose, P. W., Prlić, A., Bi, C., Bluhm, W. F., Christie, C. H., Dutta, S., Green, R. K., Goodsell, D. S., Westbrook, J. D., Woo, J., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1214 · Cited by 515
Genenames.org: the HGNC resources in 2015
Gray, K. A., Yates, B., Seal, R. L., Wright, M. W., & Bruford, E. A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1071 · Cited by 492
Phase III and submission failures: 2007–2010
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471 · cited 1×
“3 million adverse event reports were collected against ∼6000 marketed drugs between 1969 and 2002 (19).”
BackgroundThe Comparative Toxicogenomics Database's 10th year anniversary: update 2015
Davis, A. P., Grondin, C. J., Lennon-Hopkins, K., Saraceni-Richards, C., Sciaky, D., King, B. L., Wiegers, T. C., & Mattingly, C. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku935 · Cited by 387
HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine
Roy, M.-L., Dumaine, R., & Brown, A. M. (1996) · Circulation · doi:10.1161/01.cir.94.4.817 · Cited by 303
Lucena, M. I., Andrade, R. J., Kaplowitz, N., García‐Cortes, M., Fernández, M. C., Romero‐Gomez, M., Bruguera, M., Hallal, H., Robles‐Diaz, M., Rodriguez‐González, J. F., et al. (2009) · Hepatology · doi:10.1002/hep.22895 · Cited by 290
Giacomini, K. M., Krauss, R. M., Roden, D. M., Eichelbaum, M., Hayden, M. R., & Nakamura, Y. (2007) · Nature · doi:10.1038/446975a · Cited by 276
Patel, H., Bell, D., Molokhia, M., Srishanmuganathan, J., Patel, M., Car, J., & Majeed, A. (2007) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-7-9 · Cited by 206
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design
Pihan, E., Colliandre, L., Guichou, J.-F., & Douguet, D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts186 · Cited by 142
Therapeutic target database update 2014: a resource for targeted therapeutics
Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1129 · Cited by 121
Idiosyncratic Toxicity: A Convergence of Risk Factors
Ulrich, R. G. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.072905.160823 · Cited by 109
Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
Thompson, R. A., Isin, E. M., Li, Y., Weaver, R. J., Weidolf, L. O. G., Wilson, I. D., Claesson, A., Page, K., Dolgos, H., & Kenna, J. G. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.11.002 · Cited by 104
Cell based approaches for evaluation of drug-induced liver injury
Greer, M. L., Barber, J., Eakins, J. A., & Kenna, J. G. (2009) · Toxicology · doi:10.1016/j.tox.2009.08.007 · Cited by 73
New active substances authorized in the United Kingdom between 1972 and 1994
Jefferys, D. B., Leakey, D., Lewis, J. A., Payne, S., & Rawlins, M. D. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00651.x · Cited by 71
Heijman, J., Voigt, N., Carlsson, L. M. S., & Dobrev, D. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.11.004 · Cited by 65
Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2015) · BMC Medicine · doi:10.1186/s12916-014-0262-7 · Cited by 65
Stephens' detection of new adverse drug reactions
Talbot, J. C. C., & WALLER, P. C. (2004) · Cited by 47
Bae, S. K., Cao, S., Seo, K., Kim, H., Kim, M., Shon, J., Liu, K., Zhou, H.-H., & Shin, J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020727 · Cited by 47
Pharmacogenetics of Drugs Withdrawn from the Market
Zhang, W., Roederer, M. W., Chen, W.-Q., Fan, L., & Zhou, H.-H. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.137 · Cited by 46
Hu, Y., & Bajorath, J. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5005509 · Cited by 33
Can Antiarrhythmic Drugs Cause Arrhythmia?
Podrid, P. J. (1984) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1984.tb01840.x · Cited by 22
Chung, J., Jang, S. B., Lee, Y. J., Park, M. S., & Park, K. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010362906 · Cited by 18
Cited by
ProTox-II: a webserver for the prediction of toxicity of chemicals
Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky318 · Cited by 3,195
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
ProTox 3.0: a webserver for the prediction of toxicity of chemicals
Banerjee, P., Kemmler, E., Dunkel, M., & Preissner, R. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae303 · Cited by 1,601
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
“The most common toxicity types associated with drug withdrawals in the United States and Europe are hepatic (21%), cardiovascular (16%), hematological (11%), neurological (9%), and carcinogenicity (8%) (Figure 2) (20).”
BackgroundADMET-score – a comprehensive scoring function for evaluation of chemical drug-likeness
Guan, L., Yang, H., Cai, Y., Sun, L., Di, P., Li, W., Liu, G., & Tang, Y. (2019) · MedChemComm · doi:10.1039/c8md00472b · Cited by 712
Metadata
- Authors
- Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Drwal, Malgorzata N.
- Preissner, Robert
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-08
- Volume
- 44
- Issue
- D1
- Pages
- D1080-D1086
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC4702851
- OpenAlex
- W2147670638
- Cited by
- 286
- References
- 45
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 35 · 2023: 36 · 2022: 27 · 2021: 28 · 2020: 37 · 2019: 24 · 2018: 30 · 2017: 12 · 2016: 12 · 2015: 1
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by-nc)
- Funders
- Bundesministerium für Bildung und Forschung
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug withdrawal, adverse drug reactions, drug toxicity, toxicity mechanisms, drug safety, drug discovery, chemical databases, protein targets, signaling pathways, physicochemical properties
- MeSH terms
- Pharmaceutical Preparations, Humans, Proteins, Signal Transduction, Internet, Polymorphism, Single Nucleotide, Drug Recalls, Safety-Based Drug Withdrawals, Databases, Pharmaceutical, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.